CSL Stock-Based Compensation 2017-2024 | CSLLY

CSL stock-based compensation for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.

  • CSL annual stock-based compensation for 2024 was $0.169B, a 21.58% increase from 2023.
  • CSL annual stock-based compensation for 2023 was $0.139B, a 18.8% increase from 2022.
  • CSL annual stock-based compensation for 2022 was $0.117B, a 27.45% increase from 2021.

CSL Stock-Based Compensation 2017-2024 | CSLLY

  • CSL annual stock-based compensation for 2024 was $0.169B, a 21.58% increase from 2023.
  • CSL annual stock-based compensation for 2023 was $0.139B, a 18.8% increase from 2022.
  • CSL annual stock-based compensation for 2022 was $0.117B, a 27.45% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$247.1B
Amgen (AMGN)$155.3B
Gilead Sciences (GILD)$141.6B
Vertex Pharmaceuticals (VRTX)$99.7B
Bristol Myers Squibb (BMY)$96B
GSK (GSK)$80.7B
Regeneron Pharmaceuticals (REGN)$60.7B
Alnylam Pharmaceuticals (ALNY)$58.2B
Argenex SE (ARGX)$41.5B
Insmed (INSM)$27.1B
BioNTech SE (BNTX)$25.3B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$20B
Incyte (INCY)$16.6B
Genmab (GNMSF)$16.2B
Genmab (GMAB)$15.6B
Illumina (ILMN)$15.3B
Ascendis Pharma (ASND)$11.7B
BioMarin Pharmaceutical (BMRN)$11.2B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.9B
Exelixis (EXEL)$10.2B
Moderna (MRNA)$9.9B
Verona Pharma American Depositary Share (VRNA)$9.1B
Bio-Techne Corp (TECH)$8.9B
Exact Sciences (EXAS)$8.6B
Halozyme Therapeutics (HALO)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.9B
Guardant Health (GH)$7.7B